Results 91 to 100 of about 65,998 (238)

Radiotherapy and Immunotherapy In Hepatocellular Carcinoma: Priming the Tumor Immune Microenvironment From Bench To Bedside

Precision Radiation Oncology, EarlyView.
The dual immunomodulatory network of radiotherapy in hepatocellular carcinoma. Radiotherapy initiates its effects by inducing immunogenic cell death and DNA double‐strand breaks. Immune Activation: Cytosolic DNA from damaged cells activates the cGAS‐STING pathway, triggering IRF3/NF‐κB‐mediated type I interferon production. This enhances dendritic cell
Zhigang Fu, Yang Zhang, Zuomin Wang, Zongjuan Li, Shisuo Du   +4 more
wiley   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

Therapeutics and Clinical Risk Management, 2019
Shi Zhou,* Samrat Khanal,* Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Purpose: The aim of this study
Zhou S, Khanal S, Zhang H
doaj  

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

Journal for ImmunoTherapy of Cancer
Background Pancreatic cancer is one of the deadliest cancer types and represents a major unmet medical need. CheckMate 032 investigated safety and efficacy of nivolumab monotherapy and nivolumab plus ipilimumab with/without cobimetinib in advanced ...
Padmanee Sharma, Asim Amin, Dung T Le, Michael A Morse, Marina Tschaika, Matthew H Taylor, Margaret Callahan, Katriina J Peltola, Frederic J Kaye, Eileen M O'Reilly, Stephanie Meadows Shropshire, Shaun O'Brien   +11 more
doaj   +1 more source

Baseline Neutrophil‐To‐Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non‐Small Cell Lung Cancer: A Two‐Cohort Study With Retrospective Discovery and Prospective Validation

Respirology, EarlyView.
The association between baseline neutrophil‐to‐lymphocyte ratio (NLR) and severe checkpoint inhibitor pneumonitis (CIP) was analyzed in discovery retrospective and validation prospective cohorts. Higher baseline NLR (≥ 4.75) was associated with increased severe CIP incidence in both cohorts.
Tetsu Hirakawa, Kakuhiro Yamaguchi, Shun Takao, Nobuhiro Kanaji, Naoko Matsumoto, Kozue Miyazaki, Tamio Okimoto, Chihiro Ando, Hisao Higo, Masaaki Yanai, Koji Kurose, Yasunari Nagasaki, Masako Watanabe, Kosuke Oyama, Yuko Toyoda, Yoshihiro Taguchi, Shimpei Tada, Kiyofumi Shimoji, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Hiroshi Iwamoto, Hironobu Hamada, Noboru Hattori   +24 more
wiley   +1 more source

Design, synthesis and activity evaluation of tetrahydroisoquinoline‐based programmed cell death ligand 1 inhibitors

Smart Molecules, EarlyView.
Based on a 3D‐quantitative structure‐activity relationship pharmacophore model, structural optimization of Y6 yielded Y7f. Mechanistic studies revealed that Y7f acted as a programmed death receptor 1/programmed cell death ligand 1 (PD‐L1) interaction inhibitor by inducing PD‐L1 dimerization. Y7f restored T‐cell function.
Menglin Yu, Sen Cai, Yanyan Pan, Heshuang Wang, Fengwu Zhang, Aiyu Ma, Shixuan Lv, Xiuhan Guo, Shisheng Wang, Qiling Song, Chunyan Ma, Shuai Wang, Li Zhang, Jian Wang, Qingwei Meng, Yueqing Li   +15 more
wiley   +1 more source

Painful Bilateral Necrosis of the Scalp

JEADV Clinical Practice, EarlyView.
Zoé Dumesnil, Manuel Croix, Anael Dumont, Kottler Diane, Mohamed‐Taha Tagmouti, Anne Dompmartin, Jean‐Matthieu L'Orphelin   +6 more
wiley   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source

Diffuse Skin Sclerosis in a Patient With Lung Cancer

JEADV Clinical Practice, EarlyView.
Anna‐Sophia Leven, Eva Hadaschik, Alpaslan Tasdogan   +2 more
wiley   +1 more source